WorldPharmaNews
Search ...
Home
Business
Research
Events
Regulatory
Bristol-Myers Squibb
Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases.
www.bms.com
.
Bristol-Myers Squibb RSS Channel
Filters
Display #
5
10
15
20
25
30
50
100
All
Filter
List of articles in category Bristol-Myers Squibb
Title
Published Date
Onglyza® (saxagliptin) achieves primary safety endpoint in SAVOR cardiovascular outcomes trial
02 September 2013
Bristol-Myers Squibb and Samsung BioLogics announce biopharmaceutical manufacturing relationship
29 July 2013
Bristol-Myers Squibb reports second quarter 2013 financial results
25 July 2013
Bristol-Myers Squibb and Simcere enter partnership to co-develop and co-commercialize Orencia® SC (abatacept) in China
14 June 2013
FDA grants Priority Review to Bristol-Myers Squibb and AstraZeneca's Metreleptin
04 June 2013
Bristol-Myers Squibb and Pfizer announce publication of ARISTOTLE subanalysis in Circulation
06 May 2013
Bristol-Myers Squibb reports first quarter 2013 financial results
25 April 2013
Bristol-Myers Squibb enters a collaboration agreement with Reckitt Benckiser Group plc
12 February 2013
Bristol-Myers Squibb reports fourth quarter financial results
24 January 2013
FDA approves ELIQUIS® (apixaban) to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation
02 January 2013
Bristol-Myers Squibb Foundation's Together on Diabetes™ marks World Diabetes Day
14 November 2012
Portola, Bristol-Myers Squibb and Pfizer sign clinical collaboration agreement to study ELIQUIS® and Portola's universal Factor Xa inhibitor antidote PRT4445
01 November 2012
Bristol-Myers Squibb reports third quarter 2012 financial results
24 October 2012
YERVOY® (ipilimumab) awarded prestigious Prix Galien USA 2012 for best biotechnology product
17 October 2012
ELIQUIS® (apixaban) demonstrates consistent reductions in stroke and systemic embolism, major bleeding and mortality
02 October 2012
Vanderbilt University and Bristol-Myers Squibb sign collaboration agreement to develop novel treatments for parkinson's Disease
23 September 2012
Bristol-Myers Squibb and AstraZeneca complete expansion of diabetes alliance
09 August 2012
Bristol-Myers Squibb Foundation awards $1.6 million in grants
06 August 2012
Bristol-Myers Squibb and AstraZeneca expand diabetes alliance
01 July 2012
Bristol-Myers Squibb and Emory University announce partnership
20 June 2012
Start
Prev
1
2
3
4
5
6
7
8
9
10
Next
End
Business & Industry
Novartis shares Zolgensma long-term data demonstrating sustained durability up to 7.5 years post-dosing; 100% achievement of all assessed milestones in children treated prior to SMA symptom onset
CPHI Pharma Awards open to global innovators, scientists, entrepreneurs and social leaders
Insilico Medicine brings AI-powered "ChatPandaGPT" to its target discovery platform
BlueRock Therapeutics to incorporate wearable and invisible contactless digital health technologies from Rune Labs and Emerald Innovations in Parkinson's disease clinical trial
Novartis Tafinlar + Mekinist approved by FDA for pediatric patients with BRAF V600E low-grade glioma
Research & Development
Candidate found to inhibit malignant melanoma growth
A nasal spray protects against coronavirus infection - Effective also against recent immune-evasive variants
'Biohybrid' device could restore function in paralysed limbs
Scientists use tardigrade proteins for human health breakthrough
DNA treatment could delay paralysis that strikes nearly all patients with ALS
Scientists reveal a potential new approach to treating liver cancer
Normalizing tumor blood vessels may improve immunotherapy against brain cancer
Conferences & Events
SAE Media Group proudly presents the 4th Annual AI in Drug Discovery Conference
SAE Media Group's 6th annual 3D Cell Culture Conference
CPHI Frankfurt returns to pre-pandemic strength as pharma industry booms again
14th Annual RNA Therapeutics: Investigating the next generation of genetic medicine through RNA based therapies
CPHI Excellence in Pharma Award Winners 2022
CPHI Frankfurt Report predicts huge funding overhang to drive contract services growth
CPHI Frankfurt 2022: Global pharma confidence hits record high in the annual CPHI Pharma Index
Regulatory Affairs
FDA approves first over-the-counter naloxone nasal spray
FDA grants Accelerated Approval for Alzheimer's disease treatment
FDA approves new HIV drug for adults with limited treatment options
FDA approves first gene therapy for the treatment of high-risk, non-muscle-invasive bladder cancer
FDA approves first gene therapy to treat adults with Hemophilia B
You are here:
Home
Bristol-Myers Squibb